Creating therapies that make a difference
Novo Nordisk is a focused healthcare company.
Novo Nordisk Research & Development (R&D) applies world-class protein expertise to areas where we can obtain a leading position in enabling patients to significantly improve their therapeutic outcomes.
Novo Nordisk has pioneered diabetes research and therapeutic development for more than 85 years. Throughout the years we have refined our competencies in protein science and technologies, using them to advance treatment options for people living with serious diseases areas like diabetes, haemophilia and chronic inflammatory conditions.
Our aim is to:
- expand our position as the world’s leading diabetes-care company
- ensure leadership in the biopharmaceutical areas of haemophilia and growth hormone deficiency
- apply our protein technology platform to build a sustainable presence within inflammation
We recognise the value of collaborating with others to find innovative treatment solutions, so we nurture extensive research networks, actively seek new partners and welcome young researchers in our various fellowship programmes while also supporting innovative research ideas through our global scholarship and awards programmes.
Novo Nordisk is committed to realising our strategic aspirations in our focus disease areas. We allocate an increasing share of our revenues to R&D, while ensuring high ethical standards throughout our value chain. Our research bioethics including animal testing consistently earns high external ratings; the Dow Jones Sustainability Indexes granted Novo Nordisk the maximum score of 100 points for the fourth consecutive year in 2010.
Our Strategy
Clear strategy for the therapeutic areas we focus on.
